Conditions: Prostate Cancer
Keywords: bone turnover hormone-naïve prostate specific antigen Prostate Cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 67
Healthy volunteers: no

Brief summary:
To evaluate the effect of enzalutamide on prostate specific antigen (PSA) level in men with prostate cancer.

Detailed description:

Arms:
arm 1: Participants received oral enzalutamide at 160 mg once daily for 24 weeks. Participants who had clinical benefit at Week 25 could continue to receive enzalutamide until disease progression, objective or clinical, or occurrence of an unacceptable toxicity, at the discretion of the investigator.

Interventions: intervention 1: Enzalutamide
Intervention descriptions: intervention 1: Oral

Protocol document: